With Donald J. Trump's election victory last week, Robert F. Kennedy Jr. will be able to target Food and Drug Administration oversight on many fronts, and he has made many of his goals public. Although the extent and scope of Kennedy's influence is currently unclear, the president-elect would likely place Kennedy in an oversight position that would have influence over multiple federal health agencies, including the Food and Drug Administration.
To say that Kennedy's views were unorthodox would be an understatement. The Kennedy eccentric lashed out at the U.S. “war machine” and opposed U.S. military aid to Ukraine but supported Israel's war in Gaza. He supports abortion, but he also wants to “seal down” the southern border. On the campaign trail, he embraced his status as an eccentric;
Kennedy has been very public about his desire to fire institutional experts who act on treatments that sometimes cause harm to people or are on the fringes of accepted medical practice.
Just days before last week's election, he detailed a number of products that he claimed were being “actively suppressed” by the FDA. The list includes a variety of products that have been documented to pose high levels of risk to humans, including drinking raw milk, which has been known to be a risk for decades and whose risk increased significantly with the outbreak of bird flu in March. Other items on his list of complaints include ivermectin, vitamins and various treatments involving stem cells and hyperbaric oxygen.
“The FDA’s war on public health is coming to an end,” Kennedy wrote in a social media post. “This includes research on hallucinogens, peptides, stem cells, raw milk, hyperbaric therapy, chelating compounds, ivermectin, hydroxychloroquine, vitamins, clean foods, sunlight, exercise, nutraceuticals and anything else that promotes human health but does not Patented substances are actively inhibited. If you work for the FDA and are part of this corrupt system, I have two messages for you: 1. Keep your records, 2. Pack your bags.”
(Photo: Acura Media Group)
